Predicted Trait | |
Reported Trait | Nonmucinous Epithelial Ovarian Cancer |
Mapped Trait(s) | ovarian carcinoma (EFO_0001075) |
Score Construction | |
PGS Name | PRS22_OCstepwise |
Development Method | |
Name | Stepwise method |
Parameters | NR |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 22 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000474 |
Citation (link to publication) | Hurwitz LM et al. JAMA Netw Open (2023) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 63,702 individuals (100%) |
PGS Evaluation |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
Europe PMC: 35027648 |
[
|
European | OCAC |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM018518 | PSS011005| Multi-ancestry (including European)| 11,135 individuals |
PGP000474 | Hurwitz LM et al. JAMA Netw Open (2023) |
Reported Trait: Nonmucinous Epithelial Ovarian Cancer x aspirin use interaction | — | — | Odds ratio (OR, <median): 0.85 [0.7, 1.02] Odds ratio (OR, >=median): 0.86 [0.74, 1.01] |
— | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011005 | — | — | [
|
— | African American or Afro-Caribbean (Black) |
— | OCAC | — |
PSS011005 | — | — | [
|
— | European | — | OCAC | — |
PSS011005 | — | — | [
|
— | Not reported | — | OCAC | — |